Danaher Corporation (DHR) Stock
NYSEDHR has an Alpha Score of 42 out of 100 (weak), computed on Oct 26, 2026 from 3 of 4 sub-scores. 37 members of Congress disclosed 85 trades in DHR since 2014: 41 purchases and 44 sales, most recently Kevin Hern (partial sale, Sep 2, 2026). 8 of the hedge funds AlphaScala tracks reported DHR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $407.74M. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 40.5 and its net margin 16.0% (key statistics as of Oct 22, 2026).
What is DHR's Alpha Score?
How it works →Alpha Score of 42 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 26, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Danaher Corporation (DHR)?
Most recent: Kevin Hern (partial sale, Sep 2, 2026); records start Feb 25, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-09-02 | partial sale | $1k – $15k |
| Kevin Hern R-OK · House | 2026-08-31 | sale | $15k – $50k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-12-18 | sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-11-13 | partial sale | $1k – $15k |
| Julie Johnson D-TX · House | 2025-10-07 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-09-25 | sale | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2025-09-03 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded DHR, with filing lags →Which hedge funds own DHR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 2.14M | $407.74M | +1071% |
| Citadel Ken Griffin | 944K | $179.75M | -8% |
| Renaissance Technologies Jim Simons (founder) | 761K | $144.89M | +12% |
| Third Point Dan Loeb | 540K | $102.86M | +3% |
| Tiger Global Chase Coleman | 456K | $86.86M | NEW |
| D.E. Shaw David Shaw | 412K | $78.45M | -71% |
| Duquesne Family Office Stanley Druckenmiller | 50K | $9.58M | NEW |
| Bridgewater Associates Ray Dalio | 26K | $4.89M | +1% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Danaher Corporation insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 28, 26 | Mcgrew Matthew | Executive Vice President | SELL | 14.2K | $3.3M |
| Oct 28, 26 | Mcgrew Matthew | Executive Vice President | SELL | 15.6K | $3.7M |
| Oct 28, 26 | Bouda Christopher | VP, Chief Accounting Officer | SELL | 4.3K | $1.0M |
| Oct 28, 26 | Bouda Christopher | VP, Chief Accounting Officer | SELL | 3.3K | $763K |
| Aug 21, 26 | Blair Rainer | President & CEO | SELL | 11.3K | $2.5M |
| Aug 21, 26 | Blair Rainer | President & CEO | SELL | 39.2K | $8.6M |
| Aug 21, 26 | Blair Rainer | President & CEO | SELL | 7.8K | $1.7M |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are DHR's key statistics?
Key statistics as of Oct 22, 2026
How does DHR's valuation compare with the Healthcare sector?
| Metric | DHR | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 40.5 | 27.1 | 97 |
| Net margin | 15.95% | 5.48% | 139 |
| Return on equity | 7.66% | 6.84% | 158 |
| Dividend yield (payers) | 0.49% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
DHR price chart
Powered by TradingViewWhat does Danaher Corporation do?
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services globally, with a primary focus on the United States, China, and other international markets. Operating through three key segments—Biotechnology, Life Sciences, and Diagnostics—the company provides bioprocessing technologies, consumables, and solutions that accelerate therapeutic development and manufacturing, including cell culture media, chromatography resins, filtration systems, and single-use hardware for full manufacturing suites. Its Life Sciences division supports advanced research tools, while Diagnostics offers essential testing and healthcare filtration solutions. Originally founded in 1969 and transformed through strategic acquisitions and divestitures, such as the 2023 spin-off of its environmental solutions into Veralto, Danaher now concentrates on scientific instruments and consumables in the diagnostics and research sector. Employing around 62,000 to 63,000 people under CEO Rainer Blair, Danaher plays a pivotal role in the healthcare and life sciences industries, driving innovation in biopharma production and medical diagnostics with a strong emphasis on recurring revenue streams.